The guidelines for secondary prevention of myocardial infarction (MI) in Japan were developed by the Joint Working Groups consisting of representatives of various academic societies in the field of cardiovascular diseases including the Japanese Circulation Society (JCS) and the Japanese College of Cardiology. The first edition of the guidelines were published in 2000 1 under the title of "Guidelines for the Diagnosis and The present version is the second update. We prepared this 2011 update to include evidences obtained in Japan as much as possible and to fit the current situation in Japan, where coronary intervention is a common procedure. We hope that these guidelines will be used widely in the clinical setting in Japan to improve the prognosis of patients with MI. -No resting or exercise-induced myocardial ischemia.* -No resting or exercise-induced complex arrhythmias.
-Uncomplicated myocardial infarction, coronary artery bypass surgery, coronary intervention.* -Functional capacity of 6 METs or more on graded exercise test 3 or more weeks after clinical event.
Intermediate -Mild to moderately depressed left ventricular function (EF: 31 to 49%).
-Functional capacity of less than 5 or 6 METs or more on graded exercise test 3 or more weeks after clinical event.
-Failure to comply with exercise intensity prescription.
-Exercise-induced myocardial ischemia (0.1 to 0.2 mV ST-segment depression, echocardiogram or scintigram).* High -Severely depressed left ventricular function (EF: 30% or less).
-Complex ventricular arrhythmias at rest or appearing or increasing with exercise.
-Decrease in systolic blood pressure of 15 mmHg or more during exercise or failure to rise with increasing exercise workloads.
-Survivors after cardiopulmonary resuscitation.* -Myocardial infarction complicated by congestive heart failure, cardiogenic shock and/or complex ventricular arrhythmias.
-Severe coronary artery disease and marked exercise-induced myocardial ischemia (ST-segment depression of 0.2 mV or more).
Nitrates 111-115
Class I Fast-acting nitrates such as nitroglycerin (i.e., sublingual tablet, nebulized spray or intravenous one-shot injection) should be used to treat anginal attacks. 
Class IIa

Class IIb
Patients with NYHA Class II symptoms of chronic heart fail-JCS Guidelines for Secondary Prevention of MI -The use of high-purity EPA preparation in addition to statins should be considered in patients with hyper-LDL cholesterolemia. Anti-diabetic drugs -Adequate control of blood pressure and lipid levels should be aimed in diabetic patients with MI. Nitrates -Fast-acting nitrates such as nitroglycerin (i.e., sublingual tablet, nebulized spray or intravenous one-shot injection) should be used to treat anginal attacks. Nicorandil -Long-term administration of nicorandil should be used for patients with old MI complicated by stable angina. -Nicorandil should be administered to improve the symptoms of post-infarction angina and myocardial ischemia. Calcium channel blockers -Long-acting calcium channel blockers should be used for MI patients with coronary spastic angina or those in whom coronary spasm was definitely considered to be the cause of MI, to prevent ischemic attacks. Renin-angiotensin-aldosterone system inhibitors 1. ACE inhibitors -ACE inhibitors should be administered within 24 hours after the onset of acute MI to high-risk patients who have left ventricular dysfunction (LVEF of less than 40%) or heart failure.
( 1. Supraventricular arrhythmia -Heart rate control by monotherapy or combination therapy with β-blockers, non-dihydropyridine calcium channel blockers, and/or digoxin should be performed in patients with atrial fibrillation not complicated by heart failure. -Heart rate control by β-blockers with or without digoxin should be performed in patients with atrial fibrillation complicated by heart failure due to systolic dysfunction. -Heart rate control by amiodarone should be performed in patients with atrial fibrillation complicated by heart failure due to systolic dysfunction in whom β-blockers are unusable. -Patients with unifocal PVC triggering ventricular tachycardia or ventricular fibrillation in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. -Patients with frequent PVCs associated with significant decrease in QOL or heart failure in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. -Patients in whom CRT is not effective due to ineffective pacing caused by frequent PVCs and pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. -Patients with monomorphic ventricular tachycardia complicated by cardiac dysfunction or heart failure in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. -Patients with frequent ICD discharges and in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. -Patients in whom CRT is not effective due to ineffective pacing caused by monomorphic ventricular tachycardia and pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. Patients with hemodynamically stable monomorphic ventricular tachycardia in whom pharmacotherapy is ineffective, or cannot be continued due to adverse drug reactions, or cannot be assessed for drug efficacy, or in whom catheter ablation is ineffective or impossible. -Patients with nonsustained ventricular tachycardia complicated by left ventricular dysfunction (LVEF of 35% or less) in whom sustained ventricular tachycardia/ventricular fibrillation leading to hemodynamic collapse is induced during electrophysiological study. -Patients with NYHA Class II or III symptoms of chronic heart failure despite appropriate pharmacotherapy, a LVEF of 35% or less, and nonsustained ventricular tachycardia. -Patients with NYHA Class II or III symptoms of chronic heart failure despite appropriate pharmacotherapy, a LVEF of 35% or less, and syncope of unknown etiology. 3. CRT CRT-P -Patients with NYHA Class III or ambulatory Class IV symptoms of chronic heart failure despite optimal pharmacotherapy, a LVEF of 35% or less, a QRS duration of 120 msec or more, and sinus rhythm. CRT-D -Patients with NYHA Class III or ambulatory Class IV symptoms of chronic heart failure despite optimal pharmacotherapy, a LVEF of 35% or less, a QRS duration of 120 msec or more, and sinus rhythm, and who are indicated for ICD therapy.
( Table 2' [Note] The present guidelines provide standard practices developed on the basis of substantial evidence. Since each patient has his or her unique characteristics, physicians should use these guidelines with sufficient attention given to individual circumstances, and treatment plan should always be at physician's discretion and according to clinical symptoms. The present guidelines provide no grounds for argument in case of legal prosecution and this guideline document is not provided as a peer-reviewed article or research report. 
